858 Therapeutics develops small molecule drugs targeting oncology and immunology.
858 Therapeutics has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in September 2024.
858 Therapeutics's investors include Insight Partners, New Enterprise Associates, Cormorant Asset Management, Versant Ventures, Avidity Partners.
858 Therapeutics is headquartered in San Diego, United States.
858 Therapeutics develops small molecule drugs targeting oncology and immunology.
858 Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"858 Therapeutics — Funding & Investors." VCBacked, September 26, 2024, https://www.vcbacked.co/company/858-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). 858 Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/858-therapeutics
{{cite web |title=858 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/858-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated